Zimmer Biomet Holdings EBIT

The latest EBIT for ZBH is $1.3B as of June 2026. That compares with $140M in the prior-year period — up 839.1% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Zimmer Biomet Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZBH's EBIT moved from $140M to $1.3B — a 839.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zimmer Biomet Holdings's operating scale or balance-sheet position.

Against Healthcare companies, ZBH currently prints $1.3B for EBIT, while the sector average sits near $23B. That is roughly 94.1% below the sector mean. Large gaps often invite a closer look at Zimmer Biomet Holdings's growth, margins, and balance sheet.

A EBIT figure of $1.3B for ZBH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ZBH's EBIT ($1.3B), review year-over-year change from $140M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.